This infographic examines the increased risk of low bone mineral density and impaired vertical growth observed in pediatric atopic dermatitis (AD). It also presents data demonstrating that dupilumab treatment is associated with improvements in growth compared to placebo and conventional systemic therapies in pediatric AD.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr Brian Kim discuss the burdensome itch in prurigo nodularis, the multifactorial etiology of the disease, and the multiple pathological factors that contribute to chronic itch and skin inflammation in PN.
This video supports improved clinical awareness and encourages comprehensive care strategies for patients living with both CRSwNP and asthma.
Drs. Kathryn Peterson and Ikuo Hirano and Profs. Ingrid Terreehorst and Arjan Bredenoord highlight the impact and burden of EoE on the quality of life of patients.

This infographic highlights how uncontrolled moderate‑to‑severe atopic dermatitis (AD) can lead to Cumulative Life Course Impairment (CLCI) by contributing to ongoing physical, psychological, and social burdens such as itch and sleep loss, impaired bone growth and mental health challenges. It emphasizes the importance of early and effective disease control to help reduce long‑term impact on patients.

In this exclusive KOL interview, Dr. Eric Simpson explores the cumulative, long-term impact of atopic dermatitis and highlights the potential benefits of initiating treatment early to help manage disease burden.
Join Sanofi and Regeneron for an educational symposium on type 2 inflammation, patient characteristics predictive of disease recurrence, and emerging real-world evidence for biologics in CRSwNP.
Want to test your EoE knowledge while learning more about the patient journey? Try EoE Quest, an engaging and educational interactive experience.

Join Dr Kwatra as he dives deeper into the mechanism of lesion formation in Prurigo Nodularis and the impact the development of these skin lesions have on patient life.
Prof. Tilo Biedermann and Drs. Nicole Chase and Lisa Swanson presented an engaging ADVENT educational symposium at EADV 2026 on September 30 in Vienna, Austria, focusing on the local and systemic role of type 2 inflammation in atopic dermatitis (AD) and its implications for disease management across the lifespan. The symposium explored the potential to achieve sustained optimal disease control with systemic therapy in adults, as well as the potential window of opportunity for early intervention to reduce or prevent multidimensional disease burden in pediatric AD.